Drugs / BY101921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06433726 | Mar 2024 → Jun 2025 | cancer | Chengdu Baiyu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BY101921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433726 ↗ |
| Action | Inhibit | “potent inhibitor of PARP7” NCT06433726 ↗ |
| Modality | Small molecule | “BY101921 is a novel small molecule” NCT06433726 ↗ |
| Route | Oral | “for oral administration” NCT06433726 ↗ |
| Target | PARP7 | “acts on the PARP7 catalytic subunit” NCT06433726 ↗ |